Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study
View abstract on PubMed
Summary
This summary is machine-generated.This study highlights a lack of prostate cancer (PC) awareness in the Middle East, with many patients diagnosed at advanced stages. There is a critical need for novel treatments due to common disease progression in metastatic PC.
Area Of Science
- Oncology
- Urology
- Public Health
Background
- Prostate cancer (PC) is the second most common cancer in men globally.
- Incidence of PC is increasing in the Middle East (ME).
- Real-world data on PC patient characteristics and treatment in the ME is limited.
Purpose Of The Study
- To collect real-world data on PC patient characteristics in the ME.
- To analyze disease progression patterns in ME PC patients.
- To evaluate treatment strategies and outcomes for PC in the ME.
Main Methods
- Retrospective, observational, multi-center study.
- Data from 615 male PC patients across 10 centers in Lebanon, Saudi Arabia, Iraq, and Kuwait.
- Analysis of medical records from January 2012 to December 2018/May 2019.
Main Results
- Most patients presented with localized/locally advanced PC (57.7%) or metastatic castration-sensitive PC (mCSPC) (37.4%).
- High proportion of patients at advanced TNM stages (IIIa: 40.1%, IVb: 27.8%) at diagnosis.
- Median time to metastatic disease was 84 months; disease progression common in mCSPC (35.1%) and metastatic castration-resistant PC (mCRPC) (14.8%).
Conclusions
- Advanced TNM stage at diagnosis suggests low PC awareness in the ME.
- Disease progression in metastatic PC highlights challenges in treatment.
- Urgent need for novel therapeutic strategies for advanced and metastatic PC in the region.

